Biologically Active Small Molecules

16,16-dimethyl PGD2 is a metabolically stable synthetic analog of PGD2. It enhances ADP-induced human platelet aggregation and increases systemic blood pressure in rats.

16,16-dimethyl PGD2 is a metabolically stable synthetic analog of PGD2. It enhances ADP-induced human platelet aggregation and increases systemic blood pressure in rats.

16,16-dimethyl PGE1 is a metabolically stable synthetic analog of PGE1. It induces human vascular smooth muscle contractions in vitro.

16,16-dimethyl PGE1 is a metabolically stable synthetic analog of PGE1. It induces human vascular smooth muscle contractions in vitro.

16,16-dimethyl PGE1 is a metabolically stable synthetic analog of PGE1. It induces human vascular smooth muscle contractions in vitro.

The p-(p-acetamidobenzamido) phenyl ester is a crystalline derivative of 16,16-dimethyl PGE2 and a potential prodrug.

The p-(p-acetamidobenzamido) phenyl ester is a crystalline derivative of 16,16-dimethyl PGE2 and a potential prodrug.

The p-(p-acetamidobenzamido) phenyl ester is a crystalline derivative of 16,16-dimethyl PGE2 and a potential prodrug.

The p-(p-acetamidobenzamido) phenyl ester is a crystalline derivative of 16,16-dimethyl PGE2 and a potential prodrug.

A competitive inhibitor of 15-hydroxy PGDH acts as an agonist on most EP receptor subtypes (Kd d~ 1 nM for isolated EP2 receptors) preserves the self-renewal properties while preventing the differentiation of hematopoietic stem cells during

A competitive inhibitor of 15-hydroxy PGDH acts as an agonist on most EP receptor subtypes (Kd d~ 1 nM for isolated EP2 receptors) preserves the self-renewal properties while preventing the differentiation of hematopoietic stem cells during

A competitive inhibitor of 15-hydroxy PGDH acts as an agonist on most EP receptor subtypes (Kd d~ 1 nM for isolated EP2 receptors) preserves the self-renewal properties while preventing the differentiation of hematopoietic stem cells during